A key unmet need facing psoriasis patients today is a lack of access to efficient medicines that are also attractive enough to ensure patient adherence to treatment regimens.
There has been a recent surge in research identifying CD47, known as the "don't eat me" molecule, as a target for cancer treatments.
Fitbit recently announced the release of a suite of apps and watch faces that integrate and connect the wearer with different healthcare companies, pharmacies and payers, specifically in the Diabetes, Oncology and wellness spaces.
As additional Big Pharma look to enter the field, the possibility of a healthcare bubble could be on the horizon, as small companies are bought out for too much, too early.
2/3 of the top executives recently surveyed are pushing towards a data-driven culture–but most have yet to successfully create an intelligence-driven org (IDO).
Signals is proud to announce our 273% growth rate and join Deloitte's list of fast-growth companies for the second year
How will advances in clinical trial design and companion diagnostics impact immunotherapy applications in oncology?
CRISPR applications in agriculture provide valuable use cases and lessons learned as applications more towards therapeutics
What do consumers want in their wearables devices? Signals' analysis pinpoints key unmet needs and the benefits they expect to see
Why pharmaceuticals are focusing on beyond-the-pill initiatives as the next forefront of innovation in addressing patient experience
Omnichannel tactics attempt to bridge the gap between online and offline marketing channels
Signals Analytics is proud to be named a 2016 Cool Vendor in R&D for Manufacturers by Gartner, Inc.
$10 Million raised in new funding round with Qumra Capital completes Signals Analytics Series B
Is rice more healthful than ice cream? Not necessarily, says new study released by the Weizmann Institute
Signals is proud to announce our 179% growth rate and debut on Deloitte's list of fast-growth companies